New Strategy Could Break Pancreatic Cancer’s Protective Shield

A newly identified inflammatory signaling target may help weaken the protective environment surrounding pancreatic tumors and make existing treatments more effective. Pancreatic tumors are not made up of cancer cells alone. They are surrounded by scar-like tissue, immune cells, and support cells that can shield the disease from treatment. A new study suggests that disrupting [...]

A newly identified inflammatory signaling target may help weaken the protective environment surrounding pancreatic tumors and make existing treatments more effective. Pancreatic tumors are not made up of cancer cells alone. They are surrounded by scar-like tissue, immune cells, and support cells that can shield the disease from treatment.

A new study suggests that disrupting a receptor called IL1RAP may weaken this protective system and make pancreatic cancer more vulnerable to therapy. The work, led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, is now helping shape a first-of-its-kind clinical trial. The planned study will combine an IL1RAP-targeted drug with chemoimmunotherapy before surgery in patients whose tumors can still be removed.

Why Pancreatic Cancer Resists Treatment Pancreatic cancer is especially difficult to treat because its tumors often develop a dense, fibrous microenvironment. This surrounding tissue can limit drug penetration, suppress immune responses, and help cancer cells survive under stress. That biology also helps explain why treatments that work in other cancers often have limited effects in pancreatic tumors.

Even when chemotherapy damages cancer cells, the surrounding cellular network can help the disease recover and adapt. Recent progress with KRAS-targeted drugs has generated optimism for patients with metastatic disease. However, bringing similar advances to patients with operable pancreatic cancer may take years, underscoring the need for strategies that can be tested sooner in the preoperative setting.

IL1RAP as a Signaling Hub In the study, published in JCI Insight, Jashodeep Datta, M.D., and his colleagues examined IL1RAP, a receptor that helps transmit several inflammatory signals. The researchers found that IL1RAP acts as a link among cancer cells, immune cells, and fibroblasts.

Fibroblasts are cells that help produce the structural tissue surrounding tumors. Together, these cell types create a coordinated environment that can support tumor growth and blunt the effects of treatment. “When we target IL1RAP, we are blocking a shared ‘helper’ receptor that many inflammatory signals rely on to transmit their message,” said Datta, a pancreatic and hepatobiliary surgical oncologist, co-leader of the Gastrointestinal Site Disease Group at Sylvester, and senior